| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 25.05.
| K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity | | 136 | PR Newswire |
| ST. LOUIS, May 25, 2012 /PRNewswire/ --K-V Pharmaceutical Company (the "Company") (NYSE: KVa/KVb) today announced that in view of the unusual market activity in the Company's common stock...
Mehr lesen zu:
K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity | |
| 12.04.
| K-V Pharmaceutical Company to Present at Imperial Capital 2012 Healthcare Investor Forum | | 57 | PR Newswire |
| ST. LOUIS, April 12, 2012 /PRNewswire/ --K-V Pharmaceutical Company (the "Company") (NYSE: KVa/KVb) today announced that Greg Divis, President and CEO, and Tom McHugh, Chief Financial Officer, will...
Mehr lesen zu:
K-V Pharmaceutical Company to Present at Imperial Capital 2012 Healthcare Investor Forum | |
| 02.04.
| K-V Pharmaceutical Company to Present at Needham & Company 11th Annual Healthcare Conference | | 14 | PR Newswire |
| ST. LOUIS, April 2, 2012 /PRNewswire/ --K-V Pharmaceutical Company (the "Company") (NYSE: KVa/KVb) today announced that Thomas McHugh, Chief Financial Officer, will present at the Needham & Company...
Mehr lesen zu:
K-V Pharmaceutical Company to Present at Needham & Company 11th Annual Healthcare Conference | |
| 28.02.
| The Law Firms of Harwood Feffer LLP and Stember Feinstein Doyle Payne & Kravec and KV Pharmaceutical Company Announce the Settlement of the KV Pharmaceutical ERISA Class Action Litigation | | 19 | Business Wire |
| Class Counsel Harwood Feffer LLP and Stember Feinstein Doyle Payne &
Kravec and KV Pharmaceutical Company announce that a settlement has been
preliminarily approved by...
Mehr lesen zu:
The Law Firms of Harwood Feffer LLP and Stember Feinstein Doyle Payne & Kravec and KV Pharmaceutical Company Announce the Settlement of the KV Pharmaceutical ERISA Class Action Litigation | |
| 09.02.
| K-V Pharmaceutical Announces Updated Makena® Performance Metrics and Investor Conference Call | | 56 | PR Newswire |
| ST. LOUIS, Feb. 9, 2012 /PRNewswire/ --K-V Pharmaceutical Company (the "Company") (NYSE: KVa/KVb) today reported updated performance metrics for Makena®.
Makena® was launched...
Mehr lesen zu:
K-V Pharmaceutical Announces Updated Makena® Performance Metrics and Investor Conference Call | |
| 07.12.
| UPDATE 1-K-V Pharma to pay $17 mln as Ethex settlement | | 7 | Reuters.com |
| 07.12.
| K-V Pharma (KV-A) Will Pay $17M ETHEX Settlement | | 3 | StreetInsider.com |
| 07.12.
| K-V Pharmaceutical Company Comments on Recent Settlement With the Department of Justice | | 25 | PR Newswire |
| ST. LOUIS, Dec.7, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KV.A/ KV.B) (the "Company" or "K-V"), today commented on the settlement of false claims allegations with the U.S....
Mehr lesen zu:
K-V Pharmaceutical Company Comments on Recent Settlement With the Department of Justice | |
| 06.12.
| KV Pharma (KV.A) to Pay $17M to Settle Ethex Allegations, DoJ Says | | - | StreetInsider.com |
